The Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Individuals with Diabetes Mellitus Type two and Heart Failure
Main Article Content
Abstract
Background: SGLT2 Inhibitors are a new family proven by FDA to treat diabetes mellitus type two and because of their cardioprotective effect now used widely in diabetic patients suffering from heart failure.
Objective: This study’s goal is to determine the effect of cardioprotective SGLT2 Inhibitors on patients with diabetes mellites and heart failure.
Methods: We collected and analyzed fourteen articles, which were published from the period 2015 to 2023, all looking for an influence of SGLT2 inhibitors on diabetics with heart failure.
Results: all SGLT2 inhibitors caused a significant decrease in symptoms and hospitalization, morbidity, and mortality and expand the life pattern in patients with heart failure due to the cardiac inflammation reduction, hypertrophy reduction and fibrosis reduction by which they reduce cardiac remodeling.
Conclusion: All SGLT2 inhibitors are equally effective in mortality and morbidity reduction in diabetic patients suffering from HF.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European Journal of Pharmaceutical Sciences. 2016 Oct 10;93:244-52.
II. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocrine reviews. 2011 Aug 1;32(4):515-31.
III. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. Basic to Translational Science. 2020 Jun 1;5(6):632-44.
IV. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Therapy. 2014 Dec;5:355-66.
V. Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, Swab M, Hache J, Curnew D, Nguyen H, Gamble JM. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ open. 2019 Jan 1;9(1):e022577.
VI. Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes & metabolism. 2014 Dec 1;40(6):S28-34.
VII. McMurray JJ, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M. The Dapagliflozin and Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics. European journal of heart failure. 2019 Nov;21(11):1402-11.
VIII. Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Fosbøl E, Bruun NE, Videbæk L. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials. 2019 Dec;20(1):1-8.
IX. Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH. Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized trial. Annals of internal medicine. 2021 Aug;174(8):1065-72.
X. Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018 Jul 31;138(5):458-68.
XI. Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovascular diabetology. 2019 Dec;18(1):1-3.
XII. Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJ, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, Neal B. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC: Heart Failure. 2020 Jan;8(1):57-66.
XIII. Care D. Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021; 44 (Suppl. 1): S125–S150. Diabetes Care. 2021 Sep;44.
XIV. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. Journal of the American College of Cardiology. 2021 Jan 26;77(3):243-55.
XV. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W. Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine. 2020 Oct 8;383(15):1413-24.
XVI. Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F, Shah SJ. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine. 2022 Sep 22;387(12):1089-98.
XVII. Nakayama H, Ohtsuka Y, Kawahara M, Nakamura Y, Iwata S, Yoshinobu S, Soga R, Oshige T, Kawano S, Kakino S, Tsuruta M. Changes in body composition during SGLT2 inhibitor treatment and their relevance to the improvement of insulin sensitivity. Diabetes Research and Clinical Practice. 2016;1(120):S50-1.
XVIII. Pinto LC, Rados DV, Remonti LR, Kramer CK, Leitao CB, Gross JL. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetology & metabolic syndrome. 2015 Dec;7(1):1-2.
XIX. Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF, Lee AS. The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovascular diabetology. 2019 Dec;18(1):1-3.
XX. Singh JS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, Choy AM, Gandy S, George J, Khan F, Pearson ER. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial. Diabetes care. 2020 Jun 1;43(6):1356-9.